Treatment of human diseases involving dysregulation or dysfuncti

Details Treatment of human diseases involving dysregulation or dysfuncti Treatment of human diseases involving dysregulation or dysfuncti

1992-11-23

1994-04-12

Waddell, Frederick E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

A61K 3170

Patent

active

053025830

ABSTRACT:
A method of preventing, treating and/or controlling diseases caused by dysregulation and/or dysfunction of various portions of the nervous system which comprises administering to a patient, an effective amount of a compound of the avermectin family, e.g. ivermectin, in single or multiple doses of up to 1.6 mg/kg at intervals of from 3 days to 4 months.

REFERENCES:
patent: 4171314 (1979-10-01), Chabala et al.
patent: 4173571 (1979-11-01), Chabala et al.
patent: 4199569 (1980-04-01), Chabala et al.
patent: 4201861 (1980-05-01), Mrozik et al.
patent: 4206205 (1980-06-01), Mrozik et al.
patent: 4310519 (1982-01-01), Albers-Schonberg et al.
patent: 4333925 (1982-06-01), Buhs et al.
patent: 4831017 (1989-05-01), Egerton
patent: 4853372 (1989-08-01), Williams et al.
patent: 4963667 (1990-10-01), Chiu et al.
patent: 5070015 (1991-12-01), Pentuch et al.
Crichlow, et al., Neuropharmacol., 25(10), 1085-1088 (1986).
Diggs, et al., Laboratory Animal Science, 40(1), 68-71 (1990).
Conn's Current Therapy (1992) pp. 803-807 and 1049-1074.
Bennett, JAVMA, 189, 100-104 (1986).
Chalmers, et al., Eur. J. Pharmacol., 129, 371-374 (1986).
Martin, et al., Br. J. Pharmacol., 98, 747-756 (1989).
Marx, Research News, 151, 1317 (1991).
Gisslinger, et al., Lancet, 336, 1078 (1990).
Levine et al., Science, 226, 547-549 (1984).
Thompson et al., Ann. Rheum. Dis. 21, 370-77 (1962).
Bland et al., Arthritis and Rheum., 11, 72-79 (1968).
Knutsson, et al., Scand. J. Rehabil. Med., 12, 93-106 (1980).
Knutsson, et al., J. Neurol. Sci., 53, 187-204 (1982).
Kugelberg, Electroenceph. Clin. Neurophysiol. Suppl 22 (1962) 103-111.
Pacque, et al., Lancet, 335, 1377-1380 (1990).
Pacque, et al., Lancet, 336, 1486-1489 (1990).
Campbell, et al., Science, 221, 823-829 (1983).
Campbell, et al., J. Vet. Pharmacol. Therap., 7, 1-16 (1984).
Terada, et al., Exp. Parasitol., 57, 149-157 (1984).
Coward, Triangle, 20, 151-158 (1981).
Davies, Br. J. Pharmacol., 76, 473-481 (1982).
Davies, et al., Br. J. Pharmacol., 78, 137-142 (1983).
Sayers, et al., Arzneimittel-Forschung 30, 793-803 (1980).
Hagbarth, J. Neurol. Neurosurg. Psychia., 23, 222-227 (1960).
Hagbarth, et al., J. Neurol. Neurosurg. Psychia, 31 207-213 (1968).
Hassan, et al., J. Neurol. Neurosurg. Psychia, 43, 1132-1136 (1980).
Knutsson, Triangle, 21, 13-20 (1982).
Kerr, et al., Brain Res., 405, 150-154 (1987).
Price, et al., Nature, 307 71-74 (1984).
Bowery et al., Neuropharmacol., 23, 219-234 (1984).
Olsen, et al., FASEB J., 4, 1469-1480 (1990).
Erickson, Sci. Amer., 264 (5) 124 (1991).
Porter, et al., Cleveland Clin. Quart., 51, 293-305 (1984).
McNamara, et al., Neuropharmacol. 27, 563-68 (1988).
McNamara, et al., Epilepsia, 30, 513-518 (1989) (Suppl. 1).
Avery's Drug Treatment, 3rd edition, AIDS Press (1987) pp. 1114-1116.
Sigel et al., Mol. Pharmacol., 32, 749-52 (1987).
Soderlund, et al., Biochem. Biphys. Res. Comm: 146, 692-8 (1987).
Kirkness, et al., Eur. J. Pharmacol., 150, 385-388 (1988).
Robertson, Br. J. Pharmacol. 98, 167-176 (1989).
Chu et al., Neurol., 37, 1454-59 (1987).
Bhisitkul, et al., Exp. Brain Res., 66, 659-663 (1987).
Bloom, et al., Nature, vol. 239, pp. 628-630 (1971).
Graybiel, Trends in Neurological Sciences, vol. 13, No. 7, pp. 244-253 (1990).
Carlsson, et al., Trends in Neurological Sciences, vol. 13, No. 7, pp. 272-276 (1990).
Wojcik, et al., Neuropsychopharmacology, vol. 6, No. 4, pp. 201-214 (1992).
McCann, et al., Psychomemoendicronology, vol. 9, No. 2, pp. 97-106 (1984).
Barinago, Science, vol. 258, pp. 216-216 (9 Oct. 1992).
Pons, et al., Science, vol. 252, pp. 1857-1862 (28 Jun. 1991).
Ong, et al., European Journal of Pharmacology vol. 86, pp. 9-17 (1983).
Bartholini, Medicinal Research Reviews, vol. 5, No. 1, pp. 55-75 (1985).
Clonniger, Science, vol. 239, pp. 410-416, (24 Apr. 1987).
Koob, et al., Science, vol. 242, pp. 715-723 (4 Nov. 1988).
Taylor, Science, vol. 252, pp. 1380-11381, (7 Jun. 1991).
Chu, et al., Neurology, vol. 37, pp. 1454-1459 (1987).

Affiliated with

Also associated with

Rating

Treatment of human diseases involving dysregulation or dysfuncti does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of human diseases involving dysregulation or dysfuncti, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of human diseases involving dysregulation or dysfuncti will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2098746